This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia; reperfusion injury	Hypoxia-inducible factor prolyl hydroxylase 2 (EGLN1; HIF-PH2; PHD2)	Mouse studies suggest inhibiting PHD2 could help treat ischemia. In a model of limb ischemia, mice lacking one copy of <i>Phd2</i> either systemically or only in myeloid cells were protected from necrosis and had greater arteriogenesis and physical endurance compared with wild-type controls. Next steps include cell-based screens to identify PHD2 inhibitors.	Patent application filed covering PHD2 inhibition for blood vessel normalization; available for licensing	Takeda, Y. <i>et al. Nature</i> ; published online Oct. 9, 2011; doi:10.1038/nature10507 Contact: Massimiliano Mazzone, Flanders Institute for Biotechnology, Leuven, Belgium e-mail: massimiliano.mazzone@vib-kuleuven.be
<i>SciBX</i> 4(42); doi:10.1038/scibx.2011.1178 Published online Oct. 27, 2011				